Mirion Announces Record Fourth Quarter and Record Full Year 2024 Financial Results; Reaffirms Full Year 2025 Guidance

In This Article:

  • Revenues for the fourth quarter increased 10.4% to $254.3 million, compared to $230.4 million in the same period in 2023.

  • GAAP net income was $15.9 million in the fourth quarter, compared to a GAAP net loss of $14.5 million in the same period last year; a 210% improvement. Adjusted EBITDA was $69.6 million, a 14.1% increase from $61.0 million in the same period last year.

  • GAAP net earnings per share in the fourth quarter was $0.07, compared to a GAAP net loss per share of $0.08 in the fourth quarter of 2023. Adjusted earnings per share for the quarter was $0.17, compared to $0.15 in the same period last year.

  • The company reaffirmed its full year 2025 guidance provided at the December 2024 Investor Day for revenue growth, Organic Revenue growth, Adjusted EBITDA, and Adjusted Free Cash Flow guidance and introduced Adjusted Earnings per Share guidance.

    • Total and Organic Revenue growth rates are expected to be between 4.0% to 6.0% and 5.5% to 7.5%, respectively.

    • Adjusted EBITDA is expected to be between $215 million and $230 million.

    • Adjusted Free Cash Flow is expected to be between $85 and $110 million.

    • Initial Adjusted Earnings per Share guidance is between $0.45 and $0.50 per share.

ATLANTA, February 11, 2025--(BUSINESS WIRE)--Mirion ("we" or the "company") (NYSE: MIR), a global provider of radiation detection, measurement, analysis, and monitoring solutions to the medical, nuclear, defense, and research end markets, today announced results for the fourth quarter and full year ended December 31, 2024.

"We are pleased to report record 2024 performance, with good momentum continuing into 2025," commented Mirion’s Chief Executive Officer Thomas Logan. "Both fourth quarter and full year performance marked record revenue, record adjusted EBITDA, and record adjusted EPS all while delivering on our full year guidance. We also simplified our capital structure and significantly improved our net leverage during the year."

Logan continued, "Our Nuclear & Safety and Medical Groups grew fourth quarter organic revenue and enhanced their adjusted EBITDA margin performance compared to the same period last year. The fourth quarter reflects continued progress towards the 2028 long-range plan introduced at our Investor Day."

Logan concluded, "We entered 2025 with approximately half of expected 2025 revenue in our backlog. We are advancing discussions on the $300 - $400 million of large order potential previously disclosed and see increased opportunities to bid on other large deals. Moreover, short order-cycle time flow business continues to reflect positive momentum from our key vertical markets."